welcome

Be part of advancing the treatment of Vascular Ehlers-Danlos Syndrome or VEDS with this exciting new study! Acer Therapeutics is conducting a clinical trial in the U.S. to evaluate the efficacy and safety of an investigational drug known as celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).

Acer Therapeutics is actively seeking potential participants with a confirmed diagnosis of Vascular Ehlers-Danlos Syndrome (VEDS) caused by a COL3A1 mutation who are interested in participating in this investigational trial.

Celiprolol is an investigational drug and therefore its safety and efficacy have not been established. There is no guarantee that celiprolol will receive health authority approval or become commercially available for treatment of Vascular Ehlers-Danlos Syndrome (VEDS).

A decentralized clinical trial (DCT) is a clinical trial where some or all trial-related activities will occur at locations other than traditional clinical trial sites (e.g., the participant’s home or local health care facilities). DCTs may involve a network of locations where trial personnel and local HCPs work and where trial-related services (e.g., imaging and laboratory services) are provided, all under the oversight of the investigator.

A DCT will allow some or all trial-related activities to take place at trial participants’ homes or other convenient locations, instead of having them visit research sites. By reducing barriers to participation, we expect that DCTs will increase the breadth and diversity of participants in clinical trials and improve accessibility for those with rare diseases or mobility challenges. We anticipate that this approach will facilitate the development of drugs including in areas of medical need, resulting in more treatment options and improved patient outcomes.

DCTs leverage “virtual” tools, such as telemedicine, sensory-based technologies, wearable medical devices, home visits, patient-driven virtual health care interfaces, and direct delivery of study drugs and materials to patients’ homes. In a fully decentralized clinical trial, patient recruitment, delivery and administration of study medication, and acquisition of trial outcomes data all proceed without involving in-person contact between the study team and the patient/subject.